GlaxoSmithKline Plans Texas Flu Plant to Respond to Pandemics

GlaxoSmithKline Plc and the Texas A&M University System won U.S. approval for a $91 million flu vaccine plant that can be used to produce treatments in response to pandemics or biological attacks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.